Smoking Research Study

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Philip Morris Products S.A.
ClinicalTrials.gov Identifier:
NCT01465880
First received: October 14, 2011
Last updated: December 20, 2011
Last verified: December 2011
  Purpose

The purpose of this study is to develop a fit-for-purpose biochemical verification tool that can be used to detect concomitant use of a few (less than 5) conventional cigarettes.


Condition Intervention
Smoking
Non-smoking
Other: Part A

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: A Single-centre, Dose Titration Study in Healthy Volunteers (Smokers and Non-smokers) to Evaluate the Capacity of 2-cyanoethylmercapturic Acid (CEMA) to Detect Low Level of Cigarette Smoking Exposure

Resource links provided by NLM:


Further study details as provided by Philip Morris Products S.A.:

Primary Outcome Measures:
  • Levels of CEMA, a biomarker of exposure to acrylonitrile, in 24-hour urine of smokers smoking 2 or 4 conventional cigarettes [ Time Frame: After smoking 2 or 4 conventional cigarettes, within 24 hours ] [ Designated as safety issue: No ]
    To demonstrate that CEMA, used as a urinary biomarker, can identify subjects who have smoked 4 or less conventional cigarettes


Secondary Outcome Measures:
  • Levels of CEMA in 24-hour urine, carboxyhaemoglobin (COHb) in blood and carbon monoxide in exhaled breath of smokers smoking 2 or 4 conventional cigarettes [ Time Frame: After smoking 2 or 4 conventional cigarettes, within 24 hours ] [ Designated as safety issue: No ]
    To evaluate the ability of CEMA to detect conventional cigarette use in comparison to COHb and exhaled carbon monoxide

  • Levels of CEMA, a biomarker of exposure to acrylonitrile, in 24-hour and spot urine of non-smokers [ Time Frame: 24 hours ] [ Designated as safety issue: No ]
    To evaluate the correlation between the levels of CEMA in 24-hour urine and in spot urine in non-smokers


Enrollment: 88
Study Start Date: July 2011
Study Completion Date: November 2011
Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: Part B. Healthy Caucasian adult non-smokers
Non-smokers
Experimental: Part A.Healthy Caucasian adult smokers
No product will be investigated in this study. Smokers will smoke their own conventional cigarettes only.
Other: Part A
Smoking abstinence, smoking 2 and 4 cigarettes

Detailed Description:

This study will be performed in two parts. The first part, Part A, is a dose titration study in healthy smokers with incremental cigarette consumption performed in confinement. The second part, Part B, is an observational study on healthy non-smokers in an ambulatory setting

PART A (smokers only)

A screening visit will be conducted within 4 weeks prior to admission to the investigational site. The 8-day confinement period consists of the admission day (Day1), 1 day ad-libitum smoking (Day0), 3 days of smoking abstinence (Day1-3), 2-day exposure period smoking 2 and 4 cigarettes (Day4-5), and the day of discharge (Day6) followed by a 7-day safety follow-up period. Urine collection will be performed for each subject from Day0 to Day5 in 4 intervals.

PART B (non-smokers)

Screening visit will be conducted within 4 weeks prior to the ambulatory Visit 1 (collection of 24-hour urine and spot urine) to the investigational site. The minimum interval between the screening and Visit 1 is of 7 days.

  Eligibility

Ages Eligible for Study:   23 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Common criteria to smokers and non-smokers

  1. Subject is able to understand the information provided in the Subject Information sheet and Informed Consent Form (ICF)
  2. Subject has signed the ICF
  3. Subject of Caucasian origin
  4. Aged from 23 to 55 years
  5. Having acceptable health conditions as judged by the Investigator at the screening visit based on clinical laboratory parameters (clinical biochemistry, urine analysis and standard haematology), spirometry, serology, urine drug screen, vital signs, physical examination, ECG, and medical history

    Specific to smokers

  6. Current smoker based on self-reporting who smoke 5 to 15 commercially available non-mentholated conventional cigarettes (no brand restrictions) with a maximum tar yield of 10 mg (ISO method, as labelled on the cigarette package) smoking at least for the last 3 consecutive years. The smoking status will be verified at screening based on a urinary cotinine test (cotinine ≥200ng/ml)
  7. Subject is willing to smoke according to the smoking regimen of the study

    Specific to non-smokers

  8. Non-smoker based on self-reporting who have not used any tobacco or nicotine containing product including commercially available cigarettes, hand-rolled cigarettes, cigars, pipes, snuff, electronic cigarettes, similar devices, and nicotine replacement therapy within the last 12 months. The non-smoking status of the subject will be verified at screening based on a urinary cotinine test (cotinine <200ng/ml)

Exclusion Criteria:

Common criteria to smokers and non-smokers

  1. As per judgement of the Investigator, any subject who cannot participate in the study for any reason (e.g., medical, psychiatric and/or social reason)
  2. Any clinically relevant gastrointestinal, renal, hepatic, neurological, haematological, endocrine, oncological, urological, immunological and cardiovascular diseases or any other condition including clinically significant abnormal laboratory parameters that, in the opinion of the Investigator, could jeopardise the safety of the subject or impact the validity of the study results
  3. Lung cancer, upper respiratory tract cancers, chronic respiratory diseases or any other clinically significant pulmonary diseases according to the judgement of the Investigator
  4. Any medical conditions requiring smoking cessation (e.g., recent acute cardiovascular event, diabetes mellitus, Chronic Obstructive Pulmonary disease)
  5. Subject with body mass index < 18.5 or ≥ 30 kg/m2
  6. As per judgement of the Investigator, medical conditions which require or will require in the course of the study a medical intervention (e.g., start of treatment, surgery, hospitalisation) which may interfere with the study participation and/or study results
  7. Donation or receipt of whole blood or blood products within 3 months prior to the screening visit
  8. Participation in any clinical studies within 3 months before the screening visit
  9. Current or former employee of the tobacco industry, or of their first-degree relatives (parent, sibling, child)
  10. Employee of the investigational site or any other parties involved in the study or of their first-degree relatives (parent, sibling, child)
  11. Enrolled in the same study at a different time (i.e., each subject can be in the study population only once)
  12. Subject who is legally incompetent, physically or mentality incapable of giving consent (e.g., emergency situation, under guardianship, subject in a social or sanitary establishment, prisoners or subject who are involuntarily incarcerated)
  13. Positive alcohol test and/or history of alcohol abuse that could interfere with subject's participation in study
  14. Positive urine drug tests (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine and opiates)
  15. Positive serology test (HbsAg, HCV, HIV)

    Specific to smokers

  16. Subject who has used any nicotine-containing products other than commercially available cigarettes (either a tobacco-based product or nicotine-replacement therapy) as well as electronic cigarettes and similar devices within 1 month prior to the screening visit

    Additionally, women of childbearing potential must be excluded if:

  17. Subject is pregnant (does not have negative pregnancy tests at screening and at admission) or breastfeeding
  18. Subject does not agree to use an acceptable method of effective contraception: intrauterine device, intrauterine system, established use of oral/injectable/implantable/transdermal hormonal methods, barrier methods of contraception (condoms, occlusive caps) with spermicidal foam/gel/film/suppository, vasectomised partner or true abstinence (periodic abstinence and withdrawal are not effective methods) from screening until the end of the safety follow-up period
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01465880

Locations
United Kingdom
Simbec Research Ltd
Merthyr Tydfil, South Wales, United Kingdom, CF48 4DR
Sponsors and Collaborators
Philip Morris Products S.A.
Investigators
Principal Investigator: Salvatore Febbraro, MD Simbec Research
  More Information

No publications provided

Responsible Party: Philip Morris Products S.A.
ClinicalTrials.gov Identifier: NCT01465880     History of Changes
Other Study ID Numbers: PIPA_CEMA_01
Study First Received: October 14, 2011
Last Updated: December 20, 2011
Health Authority: United Kingdom: Research Ethics Committee

Keywords provided by Philip Morris Products S.A.:
Smoking research study

ClinicalTrials.gov processed this record on August 26, 2014